Clinical Practice Procedures:
Drug administration/Intranasal

<table>
<thead>
<tr>
<th>Policy code</th>
<th>CPP_DFA_INN_0215</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>February, 2015</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to intranasal (NAS) drug administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless stated otherwise.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>February, 2018</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
**Intranasal**

**Intranasal (NAS)** drug administration involves the administration of aerosoled medication via a Mucosal Atomisation Device (MAD Nasal™) directly on the highly vascularised nasal mucosa.[1]

Atomised nasal medications offer rapid absorption across mucosal membranes to the blood stream.[2,3]

**MAD Nasal™ (Intranasal Mucosal Atomisation Device)[1]**

### Indications
- The administration of medications via the NAS route

### Contraindications
- Suspected nasal fractures
- Blood/mucous obstructing the nasal passage

### Complications
- Underdosing if not administered correctly
- Mild, short lasting nasal discomfort (typically burning) from the drug itself
1. Withdraw the required dose of medication into the supplied MAD Nasal™ Syringe (an extra 0.1 mL of medication should be drawn up to account for the dead space in all unprimed devices).

2. Connect the MAD Nasal™ device to the syringe via the Luer-Lok™ connector.

3. Place the tip of the MAD Nasal™ snugly against the nostril aiming slightly upwards and outward (towards the top of the ear):
   - For volumes between 0.5 mL and 2.0 mL optimise drug absorption by delivering half the dose into each nostril (doubles the surface area available for absorption).
   - If volumes of > 2 mL are required, an alternative route of administration should be sought.

4. Briskly compress the syringe plunger to deliver the medication.